Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This clinical trial tested a new inhaled powder called TQC3721 in 195 people with moderate to severe COPD. The study compared the drug to a placebo to see if it could improve lung function over four weeks. The goal was to find a safe and effective new treatment option for COPD.

This study tested an investigational drug called TQC2731 in 205 adults with severe asthma that is not well controlled by current treatments. Participants received either one of three doses of TQC2731 or a placebo as a shot every 4 weeks for about a year. The main goal was to see …

This study tested a new drug called TQA3605 in 122 adults with chronic hepatitis B who still had low levels of virus despite standard treatment. Participants took either TQA3605 or a placebo alongside their usual antiviral pills for 24 weeks. The goal was to see if adding TQA3605…

This study tested a new drug called TQ05105 in 107 people with moderate to high-risk myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen. The goal was to see if TQ05105 could shrink the spleen better than the standard drug hydroxyurea. Participants too…

This early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …

This study tested a new drug (TQB3616) combined with fulvestrant in 122 people with a type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see if the combination could shrink tumors or slow the cancer's growth. Participants had either received one prior tr…

This study tested whether adding the experimental drug TQB3616 to standard hormone therapy (fulvestrant) can help slow cancer growth in people with a common type of advanced breast cancer (HR-positive, HER2-negative). About 293 women took part, receiving either the drug combo or …

This study tested a new drug combination (TQB2618 plus penpulimab) in 47 people with advanced nasopharyngeal carcinoma that had come back or spread. Some participants had already tried standard treatments, while others were new to therapy. The goal was to see if the combination w…

This early-phase study tested a new daily pill called TQB3616 in 40 adults with advanced breast cancer that had stopped responding to standard hormone therapy. The pill works by blocking a protein that helps cancer cells multiply. The main goals were to find a safe dose and under…

This early-phase trial tested an experimental drug called AL2846 in 33 people with a type of thyroid cancer that no longer responds to standard treatments. The goal was to see if the drug could shrink tumors or slow the cancer's growth. Participants took the drug by mouth, and do…

This phase 1 trial tested how TQ05105 tablets, a drug for myelofibrosis, interact with other drugs that affect liver enzymes. 40 healthy adults took TQ05105 alone and with itraconazole or rifampicin. Researchers measured drug levels and safety to understand how these combinations…

This study checked if a new generic version of eltrombopag (a drug that helps increase low blood platelet counts) works the same as the original brand-name drug. Thirty-six healthy Chinese adults took a single dose of each version after a meal, and researchers compared drug level…

This completed Phase 1 study looked at how the antibiotic TQD3524 behaves in 48 people with kidney problems who have drug-resistant bacterial infections. Researchers measured drug levels in the blood and urine after a single dose to understand safety and how the body processes th…

This study gave a single dose of a radioactive-labeled drug, TQ05105, to 6 healthy Chinese men. Researchers measured how much of the drug left the body in urine and stool, and how it changed in the blood. The goal was to understand how the drug is broken down and removed, not to …

This study looked at how the body processes an experimental antibiotic called TQD3606 in people with different levels of kidney function. 32 adults received a single dose, and researchers measured drug levels in blood and urine. The goal was to understand safety and drug clearanc…